m-001 influenza vaccine
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2011 (NCT01419925)
Timeline
Indications
Mechanism of action
- Influenza A virusImmunity, active
Influenza A virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- m-001 influenza vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03450915 | Phase 3 | Aug 31, 2018 | BiondVax Pharmaceuticals |
| NCT01419925 | Phase 2 | Aug 1, 2011 | BiondVax Pharmaceuticals, Tel Aviv University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BiondVax Pharmaceuticals | For profit | 2 | 2 | 2 | 2011 |
| Tel Aviv University | Academic/Hospital | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1